Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo

Oncotarget

Volumn 5, Issue 3, 2014, Pages 775-787

  Goc, Anna ^a,b   Al Husein, Belal ^a,b   Katsanevas, Katerina ^a   Steinbach, Alison ^a   Lou, Uvette ^a   Sabbineni, Harika ^a,b   DeRemer, David L ^a   Somanath, Payaningal R ^a,b,c  

^a UNIVERSITY OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Dasatinib; GSK 3; Prostate cancer; Src; Tyr 216

Indexed keywords

DASATINIB; DOCETAXEL; GLYCOGEN SYNTHASE KINASE 3; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; TYROSINE; 3-(3-CHLORO-4-HYDROXYPHENYLAMINO)-4-(4-NITROPHENYL)-1H-PYRROLE-2,5-DIONE; AMINOPHENOL DERIVATIVE; MALEIMIDE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE SILENCING; GSK3 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN TARGETING; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL GROWTH; DISEASE COURSE; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMINOPHENOLS; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DISEASE PROGRESSION; ENZYME ACTIVATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MALEIMIDES; MICE; MICE, NUDE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PYRIMIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THIAZOLES; TRANSFECTION;

EID: 84896870460     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1770     Document Type: Article

References (59)

1. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275(5308):1943-1947.
2. Boormans JL, Korsten H, Ziel-van der Made AC, van Leenders GJ, Verhagen PC and Trapman J. E17K substitution in AKT1 in prostate cancer. Br J Cancer. 2010; 102(10):1491-1494.
3. Goc A, Al-Husein B, Kochuparambil ST, Liu J, Heston WW and Somanath PR. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer. Int J Oncol. 2011; 38(1):267-277.
4. Kochuparambil ST, Al-Husein B, Goc A, Soliman S and Somanath PR. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther. 2011; 336(2):496-505.
5. Goc A, Kochuparambil ST, Al-Husein B, Al-Azayzih A, Mohammad S and Somanath PR. Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. BMC Cancer. 2012; 12:409.
6. Goc A, Liu J, Byzova TV and Somanath PR. Akt1 mediates prostate cancer cell microinvasion and chemotaxis to metastatic stimuli via integrin beta(3) affinity modulation. Br J Cancer. 2012; 107(4):713-723.
7. Al-Husein B, Goc A and Somanath PR. Suppression of interactions between prostate tumor cell integrin alpha beta and endothelial ICAM-1 by simvastatin inhibits prostate cancer micrometastasis. J Cell Physiol. 2013.
8. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J and Burgering BM. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem. 1998; 273(21):13150-13156.
9. Chen EY, Mazure NM, Cooper JA and Giaccia AJ. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res. 2001; 61(6):2429-2433.
10. Jope RS, Yuskaitis CJ and Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007; 32(4-5):577-595.
11. Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee J and Fine HA. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res. 2008; 68(16):6643-6651.
12. Mamaghani S, Simpson CD, Cao PM, Cheung M, Chow S, Bandarchi B, Schimmer AD and Hedley DW. Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis. PLoS One. 2012; 7(7):e41102.
13. Hughes K, Nikolakaki E, Plyte SE, Totty NF and Woodgett JR. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J. 1993; 12(2):803-808.
14. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N and Cleghon V. A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. Mol Cell. 2006; 24(4):627-633.
15. Kaidanovich-Beilin O and Woodgett JR. GSK-3: Functional Insights from Cell Biology and Animal Models. Front Mol Neurosci. 2011; 4:40.
16. Zhou Y, Uddin S, Zimmerman T, Kang JA, Ulaszek J and Wickrema A. Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma. 2008; 49(10):1945-1953.
17. Naito S, Bilim V, Yuuki K, Ugolkov A, Motoyama T, Nagaoka A, Kato T and Tomita Y. Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer. Clin Cancer Res. 2010; 16(21):5124-5132.
18. Miyashita K, Kawakami K, Nakada M, Mai W, Shakoori A, Fujisawa H, Hayashi Y, Hamada J and Minamoto T. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma. Clin Cancer Res. 2009; 15(3):887-897.
19. Mamaghani S, Patel S and Hedley DW. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer. 2009; 9:132.
20. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y and Minamoto T. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun. 2005; 334(4):1365-1373.
21. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 2009; 273(2):194-200.
22. Li R, Erdamar S, Dai H, Sayeeduddin M, Frolov A, Wheeler TM and Ayala GE. Cytoplasmic accumulation of glycogen synthase kinase-3beta is associated with aggressive clinicopathological features in human prostate cancer. Anticancer Res. 2009; 29(6):2077-2081.
23. Darrington RS, Campa VM, Walker MM, Bengoa-Vergniory N, Gorrono-Etxebarria I, Uysal-Onganer P, Kawano Y, Waxman J and Kypta RM. Distinct expression and activity of GSK-3alpha and GSK-3beta in prostate cancer. Int J Cancer. 2012; 131(6):E872-883.
24. Liao X, Thrasher JB, Holzbeierlein J, Stanley S and Li B. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology. 2004; 145(6):2941-2949.
25. Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC, Chari ST and Billadeau DD. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res. 2006; 12(17):5074-5081.
26. Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB and Li B. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate. 2011; 71(8):835-845.
27. Irby RB and Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene. 2000; 19(49):5636-5642.
28. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A and Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001; 20(20):2499-2513.
29. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta. 2002; 1602(2):114-130.
30. Ishizawar R and Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell. 2004; 6(3):209-214.
31. Kim LC, Song L and Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009; 6(10):587-595.
32. Fizazi K, Greco FA, Pavlidis N and Pentheroudakis G. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011; 22 Suppl 6:vi64-68.
33. Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995; 378(6559):785-789.
34. Sutherland C, Leighton IA and Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J. 1993; 296 ( Pt 1):15-19.
35. Stambolic V and Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J. 1994; 303 ( Pt 3):701-704.
36. Wang QM, Fiol CJ, DePaoli-Roach AA and Roach PJ. Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J Biol Chem. 1994; 269(20):14566-14574.
37. Agoulnik IU, Vaid A, Bingman WE, 3rd, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM and Weigel NL. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 2005; 65(17):7959-7967.
38. Schutz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV and Schrader M. Inhibition of glycogen synthase kinase-3beta counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One. 2011; 6(9):e25341.
39. Ryu YK, Lee YS, Lee GH, Song KS, Kim YS and Moon EY. Regulation of glycogen synthase kinase-3 by thymosin beta-4 is associated with gastric cancer cell migration. Int J Cancer. 2012; 131(9):2067-2077.
40. Li JS, Zhu M, Tian D, Wang MX, Wang F, Li NP and Wu RL. Glycogen synthase kinase 3beta induces cell cycle arrest in a cyclin D1-dependent manner in human lung adenocarcinoma cell line A549. Sheng Li Xue Bao. 2007; 59(2):204-209.
41. Arevalo MA and Rodriguez-Tebar A. Activation of casein kinase II and inhibition of phosphatase and tensin homologue deleted on chromosome 10 phosphatase by nerve growth factor/p75NTR inhibit glycogen synthase kinase-3beta and stimulate axonal growth. Mol Biol Cell. 2006; 17(8):3369-3377.
42. Fang X, Yu SX, Lu Y, Bast RC, Jr., Woodgett JR and Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A. 2000; 97(22):11960-11965.
43. Moore SF, van den Bosch MT, Hunter RW, Sakamoto K, Poole AW and Hers I. Dual regulation of glycogen synthase kinase 3 (GSK3)alpha/beta by protein kinase C (PKC)alpha and Akt promotes thrombin-mediated integrin alphaIIbbeta3 activation and granule secretion in platelets. J Biol Chem. 2013; 288(6):3918-3928.
44. Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, Clements JL, Sabio G, Davis RJ, Matthews DE, Doble B and Rincon M. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science. 2008; 320(5876):667-670.
45. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J, Bartholomeusz G, Li Y, Pan Y, Li Z, Bargou RC, Qin J, Lai CC, Tsai FJ, Tsai CH and Hung MC. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell. 2005; 19(2):159-170.
46. Kim L, Liu J and Kimmel AR. The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification. Cell. 1999; 99(4):399-408.
47. Lesort M, Greendorfer A, Stockmeier C, Johnson GV and Jope RS. Glycogen synthase kinase-3beta, beta-catenin, and tau in postmortem bipolar brain. J Neural Transm. 1999; 106(11-12):1217-1222.
48. Sayas CL, Ariaens A, Ponsioen B and Moolenaar WH. GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. Mol Biol Cell. 2006; 17(4):1834-1844.
49. Hartigan JA, Xiong WC and Johnson GV. Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. Biochem Biophys Res Commun. 2001; 284(2):485-489.
50. Cole A, Frame S and Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J. 2004; 377(Pt 1):249-255.
51. Bax B, Carter PS, Lewis C, Guy AR, Bridges A, Tanner R, Pettman G, Mannix C, Culbert AA, Brown MJ, Smith DG and Reith AD. The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits betacatenin phosphorylation. Structure. 2001; 9(12):1143-1152.
52. Sanchez JF, Sniderhan LF, Williamson AL, Fan S, Chakraborty-Sett S and Maggirwar SB. Glycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signaling. Mol Cell Biol. 2003; 23(13):4649-4662.
53. Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A and Kaibuchi K. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell. 2005; 120(1):137-149.
54. Chalhoub N and Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009; 4:127-150.
55. Fine B, Hodakoski C, Koujak S, Su T, Saal LH, Maurer M, Hopkins B, Keniry M, Sulis ML, Mense S, Hibshoosh H and Parsons R. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science. 2009; 325(5945):1261-1265.
56. Hsing AW, Chokkalingam AP, Gao YT, Wu G, Wang X, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Chiang T, Chen YL, Stanczyk FZ and Chang C. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2002; 11(4):337-341.
57. Kniazev Iu P, Cheburkin Iu V, Spikermann K, Peter S, Jenster G, Bangma KH, Karelin MI, Shkol'nik MI, Urbanskii AI, Evtushenko VI, Ullrich A and Kniazev PG. [Gene expression profiles of protein kinases and phosphatases obtained by hybridization with cDNA arrays: molecular portrait of human prostate carcinoma]. Mol Biol (Mosk). 2003; 37(1):97-111.
58. Cai H, Smith DA, Memarzadeh S, Lowell CA, Cooper JA and Witte ON. Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proc Natl Acad Sci U S A. 2011; 108(16):6579-6584.
59. Darby IA and Hewitson TD. Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol. 2007; 257:143-179.